Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,068,910
  • Shares Outstanding, K 48,236
  • Annual Sales, $ 1,520 K
  • Annual Income, $ -73,160 K
  • 60-Month Beta 1.79
  • Price/Sales 724.65
  • Price/Cash Flow N/A
  • Price/Book 3.59
Trade SNDX with:

Options Overview

Details
  • Implied Volatility 157.07%
  • Historical Volatility 69.74%
  • IV Percentile 72%
  • IV Rank 60.76%
  • IV High 221.12% on 12/01/20
  • IV Low 57.89% on 09/15/20
  • Put/Call Vol Ratio 0.24
  • Today's Volume 225
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 6,432
  • Open Int (30-Day) 2,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.63
  • Number of Estimates 4
  • High Estimate -0.58
  • Low Estimate -0.70
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.34 +1.28%
on 04/13/21
25.68 -19.78%
on 03/24/21
-2.31 (-10.08%)
since 03/12/21
3-Month
19.05 +8.14%
on 01/28/21
25.68 -19.78%
on 03/24/21
-2.81 (-12.00%)
since 01/13/21
52-Week
10.04 +105.18%
on 04/14/20
27.85 -26.03%
on 12/07/20
+10.68 (+107.66%)
since 04/13/20

Most Recent Stories

More News
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF

The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.

INCY : 80.65 (+0.98%)
RGEN : 212.86 (+2.82%)
NBRV : 1.4500 (-7.05%)
SNDX : 20.60 (-3.15%)
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 20.60 (-3.15%)
Vyant Bio Announces Newly Appointed Board of Directors

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of...

VYNT : 3.65 (-1.62%)
KYMR : 31.08 (-1.11%)
NANO : 35.33 (-0.81%)
LQDA : 2.56 (+1.59%)
IDRA : 1.1500 (-4.17%)
SNDX : 20.60 (-3.15%)
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD

The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.

INCY : 80.65 (+0.98%)
RGEN : 212.86 (+2.82%)
NBRV : 1.4500 (-7.05%)
SNDX : 20.60 (-3.15%)
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 20.60 (-3.15%)
Biotechs Working on Potential Preventive Measures and Cancer Treatments

, /PRNewswire/ -- Cancer research and development are a major part of the biotechnology industry, and there is always room for improvement and growth. Recently, biotech company (TSX-V:PINK) (OTCPK:PYNKF)revealed...

PINK.VN : 4.040 (unch)
PYNKF : 3.2260 (+0.50%)
SNDX : 20.60 (-3.15%)
NKTR : 18.69 (+0.05%)
SLS : 8.45 (+2.92%)
CLDX : 21.47 (+3.27%)
Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 20.60 (-3.15%)
Syndax Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 8, 2021 / Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 8, 2021 at...

SNDX : 20.60 (-3.15%)
Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 20.60 (-3.15%)
Syndax Announces Participation at Two Upcoming Investor Conferences

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 20.60 (-3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 22.88
2nd Resistance Point 22.32
1st Resistance Point 21.46
Last Price 20.60
1st Support Level 20.04
2nd Support Level 19.48
3rd Support Level 18.62

See More

52-Week High 27.85
Fibonacci 61.8% 21.05
Last Price 20.60
Fibonacci 50% 18.94
Fibonacci 38.2% 16.84
52-Week Low 10.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar